Epithelial ovarian cancer is a leading cause of morbidity and mortality from gynaecologic malignancies, with ∼22 000 new cases each year in North America. High-grade serous ovarian cancer (HGSC) is the most prevalent histological type characterised by late detection, metastasis and resistance to chemotherapy ([@bib19]). Approximately 50% of patients exhibit resistance to chemotherapy within 6 months of treatment that eventually results in death because of tumour relapse ([@bib40]; [@bib19]). A number of reports ([@bib30]; [@bib33]; [@bib3]), aimed at identifying mechanisms leading to primary chemoresistance, have revealed differential gene expression signatures in the drug-resistant patients. Recently, we showed that gene expression alterations in chemotherapy-resistant HGSC affected, among others, the NF-*κ*B pathway, drawing attention for a need to understand immunoregulation in the context of differential drug response in this tumour ([@bib13]).

Chemotherapy resistance can be defined as being either primary (innate) or secondary (acquired). Primary chemotherapy resistance is conferred by pre-existing gene expression that is inherent within the tumour, in chemotherapy-naive tumour cells or in the immediate microenvironment, that provides a state of resistance to a range of drugs. Secondary chemotherapy resistance is conferred to the tumour as a direct result of alterations that are acquired or induced by selection following exposure to chemotherapeutic agents. Chemotherapy resistance remains a major determinant of poor survival rates in HGSC, but there has been little progress in developing novel biomarkers of therapeutic response. This failure may partially be attributed to most studies being directed towards the tumour cell-intrinsic events and ignoring the contributory effects of variation in the local immune response. The role of the tumour microenvironment in the survival of tumour cells, and the dual roles of cancer immunoediting via tumour-promoting inflammation and suppression, is becoming well recognised ([@bib43]; [@bib6]; [@bib32]; [@bib2]). There is also increasing awareness that pre-existing adaptive immune status affect response to subsequent therapy across various cancers. A diverse tumour immunome was recently shown to be associated with varying clinical outcomes in colorectal cancer ([@bib4]). The abundance of tumour-infiltrating lymphocytes (TILs) correlates with survival across multiple cancers. In HGSC, ratios of CD8^+^ T cells to T regulatory cells have been associated with disease outcome ([@bib26]). Higher survival rates have been reported in tumours containing both CD8^+^ T and CD20^+^ B cells ([@bib21]; [@bib23]). In addition to the cellular infiltration, recent studies also suggest a significant role of CXC chemokines that recruit TILs in ovarian cancer ([@bib14]; [@bib27]). Although a number of studies have addressed the immune cell infiltration in the HGSC tumour microenvironment, there is insufficient information on the role of cytokine/chemokine mediators that putatively lead to a variable adaptive immune response to HGSC.

Based on our previous findings implicating NF-*κ*B to be one of the key pathways involved in chemotherapy resistance, we hypothesised that a pre-existing differential tumour immune microenvironment might lead to a variable response to chemotherapy in HGSC. We therefore analyzed differences in the tumour inflammatory environment using digital multiplexed gene expression profiling in a cohort of sensitive and resistant HGSC tumours, with an overall objective of identifying predictive markers of response to primary chemotherapy resistance. These data suggested involvement of T helper type 1 (Th1)-related factors such as signal transducer and activator of transcription 1 (STAT1), and other factors associated with an adaptive immune response that could be associated with the drug response phenotype as this protein is a key mediator of Th1 response following interferon stimulation. The rationale for determining STAT 1 expression in tumour tissues was because variation in cytokine activation and expression could arise from both tumour and a variety of the microenvironment cellular populations. Solid tumours contain a diversity of cell types recruited into close proximity (reviewed in [@bib10]), so that overall immunohistochemical quantification of STAT1 was performed. The immunohistochemistry results were obtained from an independent cohort of chemo-naive HGSC and they confirmed that STAT1 protein levels were significantly associated with progression-free survival, and implicate a role of the inflammatory tumour microenvironment in mediating chemotherapy response in this tumour.

Materials and methods
=====================

Ethics statement
----------------

This study was approved by Queen\'s University Institutional Ethics Review Board, the CHUM institutional ethics committee (Comité d\'éthique de la recherche du Centre hospitalier de l\'Université de Montréal) and Ottawa Health Research Institute (OHRI) Research Ethics Board. Informed consent from all patients was obtained before sample collection.

Patient samples for discovery study
-----------------------------------

Fresh frozen tumour tissue samples from a cohort of 34 locally advanced (stage IIa--IV) HGSC tumours were accrued from the Ontario Tumour Bank (Ontario Institute for Cancer Research) and the OHRI. All samples were collected from patients who were naive to chemotherapy and radiotherapy at the time of primary cytoreductive surgery. Samples were stored at −80 °C immediately following collection until further processing. All samples had ≥70% tumour content and were histologically classified using WHO criteria, and disease staging was performed as per the International Federation of Gynaecology and Obstetrics (FIGO) guidelines. Our discovery cohort consisted of 15 patients who exhibited progressive disease within 6 months of initiation or within 8 months of completion of chemotherapy classified as intrinsically resistant/partially resistant (R/PR) and 19 patients showing no relapse until 18 months considered intrinsically sensitive (S) to chemotherapy ([@bib13]; [@bib25]).

NanoString-based gene expression profiling
------------------------------------------

Total RNA was isolated from fresh frozen tumour tissues using Qiagen RNeasy kit (Qiagen Inc., Toronto, ON, Canada) as per the manufacturer\'s instructions. The RNA concentration and purity was estimated spectrophometrically on NanoDrop ND-100 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA).

All the RNA samples included in the study passed the quality control requirements (as assessed by the RNA integrity number or the OD 260/280 ratio) of the platform. Digital multiplexed NanoString nCounter analysis system (NanoString Technologies, Seattle, WA, USA)-based gene expression profiling was performed on 100 ng total RNA from each sample as input material according to the manufacturer\'s instructions at the Ontario Genomics Institute, Toronto. Tumour RNA samples were subjected to analysis by nCounter Human inflammation panel consisting of 184 human inflammation genes with 6 six housekeeping controls ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}) in the pre-built panel (Nanostring Technologies). In this assay, single-target transcripts in the reaction are represented in the form of colour-coded barcodes. The resulting material was incorporated into an overnight hybridisation reaction, carried out by combining 5 *μ*l of the total RNA sample with 20 *μ*l of nCounter Reporter probes in hybridisation buffer and 5 *μ*l of nCounter Capture probes for a total reaction volume of 30 *μ*l. The hybridisations were incubated at 65 °C for ∼16--20 h. During the overnight hybridisation reaction, probe pairs are present in large excess to ensure that each target finds a probe pair. Abundances of specific target molecules can then be quantified using the nCounter Digital Analyzer to count the individual fluorescent barcodes and assess target molecules present in each sample. For each assay, a high-density scan (encompassing 600 fields of view) was performed. Following hybridisation, the cartridges were analysed in the Digital Analyzer that counts (that represent the number of molecules counted) the barcodes and further tabulates them.

NanoString data analysis
------------------------

Normalisation of raw data was performed using the nSolver software (NanoString Technologies) as we previously reported ([@bib20]). The raw NanoString counts were initially subjected to normalisation for all target RNAs in all samples based on built-in positive controls. This step accounts for intersample, experimental variation such as hybridisation efficiency and post-hybridisation processing. The geometric mean of each of the controls is calculated that indicates the overall assay efficiency. The housekeeping genes are then used for mRNA content normalisation. To facilitate downstream statistical analysis, values of \<0 were blanketed and considered equal to 1. Following the initial normalisation steps, data were imported to Graphpad Prism software (GraphPad Software, Inc., La Jolla, CA, USA) for statistical analysis. Multiple *t*-tests were performed with correction for multiple comparisons using Sidak--Bonferroni method. An expression difference with a *P*-value of \<0.05 was considered statistically significant. Pearson\'s correlation analysis was performed using Graphpad Prism software to derive correlation coefficient between the expression of *STAT1* and *CXCL10* genes.

Technical validation of NanoString data by real-time quantitative PCR (qRT--PCR) in discovery cohort
----------------------------------------------------------------------------------------------------

Total RNA was subjected to cDNA synthesis using RT^2^ first-strand cDNA synthesis kit (Qiagen Inc.) as per the manufacturer\'s instructions. Custom multiplexed PCR array (SABiosciences) consisting of *CFL1*, *CREB1*, *CXCL10*, *STAT1*, *MAP3K7*, *MKNK1*, *RIPK1 and MYD88* gene targets was used to perform qRT--PCR on samples from the discovery cohort. The *GAPDH* and *GUSB* genes were included as housekeeping controls. The PCR array design also included pre-built reaction control and positive PCR control. All qRT--PCR experiments were performed in duplicates on LC-450 light cycler (Roche Diagnostics, Mississauga, ON, Canada). Data analysis was performed using relative quantification by the ΔΔCt method ([@bib31]; [@bib13]).

Independent validation of STAT1 expression on a HGSC tissue microarray (TMA) by immunohistochemistry (IHC)
----------------------------------------------------------------------------------------------------------

A TMA corresponding to an independent cohort of 213 primary chemo-naive HGSC tumours from patients who underwent surgery at the CHUM, was subjected to IHC to determine the expression of STAT1. Clinicopathological details of the cohort are summarised in [Table 1](#tbl1){ref-type="table"}. Areas of tumour were selected by a gynaecologic pathologist on haematoxylin and eosin-stained slides. Formalin-fixed, paraffin-embedded (FFPE) tumour blocks were cored using a 0.6 mm diameter needle and arrayed 1 mm apart in a grid pattern within a recipient paraffin block. The TMAs were sectioned at 4 *μ*m and the slides were stained using the BenchMark XT automated stainer (Ventana Medical System Inc., Tucson, AZ, USA). The STAT1 antibody specificity was verified using western blot analysis ([Supplementary Figure 2](#sup1){ref-type="supplementary-material"}). The optimal concentration of rabbit anti-human polyclonal STAT1 primary antibody (Abcam, Cambridge, UK; no. ab2415) was determined by serial dilutions. Antigen retrieval was carried out with Cell Conditioning 1 (Ventana Medical System Inc.; no. 950-124) for 60 min. The slides were incubated with primary STAT1 antibody (1 : 2000) at 37 °C for 60 min. Reactions were carried out using the ultraView DAB detection kit (Ventana Medical System Inc.; no. 760-500). Slides were counterstained with haematoxylin and bluing reagent (Ventana Medical System Inc.; no. 760-2021; no. 760--2037) for 4 min.

TMA scoring and IHC data analysis
---------------------------------

The TMA was scanned, digitally conserved, and manually visualised. Overall staining (including epithelial and stromal compartments) was scored according to the staining intensity in each core (value of 0 for absent, 1 for weak, 2 for moderate and 3 for strong). Each array was independently analysed in a blinded study by two independent observers. Inter-rating correlation coefficient was 83%. The average score from the two independent observers, for each respective core, was used for analysis. A total of 183 cases, for which clinical data were available, were subjected to further statistical analysis. Pearson\'s correlation coefficient was used to estimate the correlation between clinical data and the marker. Survival curves were plotted using the Kaplan--Meier curve analysis and the log-rank test was used to test for significant differences. Receiver operative characteristic (ROC) curves ([Supplementary Figure 3](#sup1){ref-type="supplementary-material"}) were used to determine the threshold value for the marker corresponding to the best sensitivity and specificity for patient progression-free survival. All statistical analyses were done using Statistical Package for the Social Science software version 16.0 (SPSS, Inc., Chicago, IL, USA). A *P*-value of \<0.05 was considered significant.

Results
=======

In this study, inflammatory gene expression profiling, by NanoString technology, of HGSCs that were clinically classified as chemotherapy resistant and sensitive displayed significant (*P*\<0.05) different expression levels in eleven genes. *STAT1*, *CXCL10*, *CREB1*, *MKNK1*, *MAP3K7*, *CFL1*, *PTK2*, *RIPK1*, *MYD88*, *CCL8* and *CCL7* were overexpressed in the sensitive cohort compared with the resistant ([Figure 1](#fig1){ref-type="fig"}), consistent with the rationale that these chemokines and immune factors could be active in the host microenvironment and promote a more favourable drug response. To determine the reproducibility of these findings, technical validation of 8 of the 11 genes was performed using qRT--PCR. Technical validation of the differentially expressed genes showed full concordance with the NanoString-based gene expression findings ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}). Of these eight genes more highly expressed in the sensitive cohort, the *interferon (IFN)-inducible protein* (*IP-10)/CXCL10* is one of the major targets of *STAT1* activation by IFN*γ*. We therefore performed Pearson\'s correlation analysis comparing the expressions of these two genes in the resistant ([Figure 2A](#fig2){ref-type="fig"}) and sensitive ([Figure 2B](#fig2){ref-type="fig"}) tumours to determine their respective correlation coefficients. This analysis revealed a strong positive correlation between the expression of *STAT1* and *CXCL10* genes within the resistant and sensitive groups with *r*^2^=0.81 (*P*\<0.001) and *r*^2^ =0.77 (*P*\<0.0002), respectively. Moreover, the greatly increased expression levels of *STAT1* in the sensitive tumours is consistent with this protein having a functional role in mediating an improved response to chemotherapy, underscoring the importance of confirming these findings at the protein level.

A total of 183 tumours were available for STAT1 IHC staining analysis based on the same classification criteria used previously ([@bib18]; [@bib39]). Following antibody optimisation ([Figure 3A](#fig3){ref-type="fig"}) a semiquantitative score from 0 to 3 ([Figure 3B](#fig3){ref-type="fig"}) was utilised to determine the overall staining intensity for the STAT1 protein. Log-rank test analysis revealed a significant (*P*=0.02) association between low STAT1 expression and decreased progression-free survival ([Figure 4](#fig4){ref-type="fig"}). These data provide additional evidence that elevated STAT1 expression together with other genes involved in the Th1 immune response may be investigated more extensively as biomarkers able to predict chemotherapy response in HGSC. Although a significant association between levels of STAT1 expression was noted upon comparison of FIGO stages I and II ([Figure 5A](#fig5){ref-type="fig"}), the difference in expression was not significant when stages III and IV were compared. Distinct STAT1 expression at the earlier stages I and II suggests that genotypic heterogeneity during tumour progression and/or the presence of a temporal element underlying the mechanism of cancer immunoediting may abrogate the need for differential STAT1 expression at later stages of the disease. Furthermore, Kaplan--Meier analysis also showed a trend, approaching significance, between decreased STAT1 expression and shorter overall survival compared with patients with longer overall survival ([Figure 5B](#fig5){ref-type="fig"}). Additional validation studies in larger cohorts are needed to confirm these findings.

Discussion
==========

Activation of both the adaptive and innate immune response to cancers are regulated by IFN ([@bib32]). Indeed, the antiproliferative roles of IFN in cancer are well established and have led to novel therapies across various cancers ([@bib7]). The *STAT1* signaling is essential to all three types of IFN pathways and therefore plays an important role in immunosurveillance ([@bib38]). Specifically, IFN-induced *STAT1* activation leads to its binding either to the interferon response elements or Gamma-activated sites, further activating the interferon-induced genes ([@bib16]). Studies in mice with defective *STAT1* activation have shown increased tumour incidence attributed to its tumour-suppressive role in breast tumourigenesis ([@bib17]; [@bib12]). Moreover, in breast cancer tissue biopsies there was selective downregulation of STAT1 protein in tumour cells relative to the surrounding stroma when analysed by immunohistochemistry ([@bib12]). These data in breast cancer tissues, and the results reported herein in ovarian cancer, highlight the key role of the microenvironment for tumour development, and the need to perform single-cell resolution analysis in order to determine protein expression in distinct cellular compartments (Koti *et al*, unpublished). The STAT1 imparts its effects by various mechanisms, such as shaping the immune cell infiltration by changes in expression within the immune compartment ([@bib29]) or by a proliferation arrest because of changes in its expression within the tumour epithelium ([@bib11]; [@bib28]). The IFN-mediated activation of *STAT1* also leads to expression of the angiostatic chemokine CXCL10 by multiple cell types including antigen-presenting dendritic cells, macrophages, T cells, fibroblasts and epithelial cells ([@bib8]). It is well established that the CXCR3/CXCL10 chemotactic axis is key to trafficking and differentiation of effector Th1 CD4+ cells, NK and CD8+ cells within inflamed tissues ([@bib8]; [@bib9]). Furthermore, increased levels of CXCL10 and CCL5/RANTES are associated with enhanced CD8+ T cell infiltration in melanoma, colorectal and gastric cancers ([@bib24]; [@bib15];, [@bib22]). Our findings are consistent with recent studies of the immune microenvironment in breast cancer, where a similar trend of decreased CXCL10 and STAT1 expression was associated with relapse ([@bib1]). Similar findings correlating increased STAT1 expression in pancreatic ([@bib37]) and colorectal ([@bib34]) cancers with improved outcomes have been reported. Interestingly, a similar pattern of overexpression of these genes has been observed in other conditions exhibiting immune-mediated tissue destruction such as allograft rejection ([@bib36]), hepatitis C infection ([@bib42]) and autoimmune diseases ([@bib41]). However, it is likely that the magnitude of change in expression required for a tumour--host immunological response in cancer in a chemo-naive environment might be quite different to the response needed in other immune-mediated disease conditions. It is noteworthy that activation of cytokine pathways in stromal and immune cells within some models of the chemotherapy-induced tumour micronenvironment may be associated with resistance, rather than sensitivity to chemotherapy ([@bib10]). However, it is likely that the mechanisms underlying natural immunosurveillance may differ to those that are responsible for chemotherapy-induced response in which cell-autonomous cytokine pathways appear to be activated ([@bib35]). As recently reviewed ([@bib12]), the observed divergence in STAT1 expression in tumour cells *in vitro* and *in vivo* reflects the artificial nature of the experimental conditions where the impact of both the stromal and immune microenvironments are lacking. Natural immunosurveillance could be attributed to the tumour cell-intrinsic characteristics such as immunogenic mutational epitopes as well as other immune escape mechanisms that might modulate antitumour immune responses, as described recently in ovarian cancer ([@bib5]). It is also possible that the off-target effects of chemotherapy on the innate and adaptive tumour immune responses (as reviewed recently ([@bib34])) alter the pre-existing state of inflammatory mediators in addition to their effect on tumour-infiltrating immune cell distribution. Such effects could further lead to variation in the type of immunological responses elicited by adjuvant chemotherapy treatment.

Collectively, these findings based on elevated *STAT1* and *CXCL10* gene expression in those tumours that responded to chemotherapy implicate the activity of a pre-existing enhanced Th1-type immune response in the tumour microenvironment. Similarly, in the resistant cohort. the existence of an under reactive immune microenvironment before exposure to chemotherapy may lead to drug resistance because of lack of a synergistic antitumour effect mediated by the immune cells. An under reactive immune microenvironment is incapable of exerting its effect in tumour cell progression because of inadequate immune surveillance, thus leading to immune escape by the tumour cells. It should be noted that the tumour cells\' intrinsic ability to modulate the secretion of cytokines and chemokines in the immediate vicinity of proliferating tumour could also provide cellular cross-talk that could contribute towards further modification of the local cellular immune/inflammatory microenvironment. Such a synergistic interaction between these compartments might be expected to lead to cellular variability in the expression levels of STAT1 in the epithelial and stromal elements. Although future longitudinal studies in this area need to be performed in order to correlate the decreased immune activation and its consequence following adjuvant chemotherapy, these initial associations provide insights into the design of novel immunomodulatory therapies that can be applied as adjuvant to current chemotherapy regimens in HGSC. The interferon pathway contributes significantly in modulating the tumour inflammatory microenvironment. Independent validation of STAT1 expression by IHC confirms its predictive role in HGSC and therefore it can be potentially be incorporated in future clinical trials following further validation in larger cohorts. Indeed, *in vitro* and *in vivo* studies are warranted to interrogate the mechanistic basis of its expression and its role in therapeutic response.

Overall, our findings provide the basis of mechanisms leading to tumour immune suppression in HGSC and warrant further investigation. In conclusion, the inflammatory gene signature suggestive of a pre-existing under reactive tumour immune microenvironment in chemotherapy-resistant HGSC patients must be explored further and taken into consideration in the design of novel adjuvant immunomodulatory therapies in HGSC.
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![**Comparison of inflammatory gene expression levels in chemotherapy-resistant *vs* -sensitive high-grade serous ovarian tumours.** The profile of inflammatory markers in the two study cohorts was determined by NanoString nCounter platform. Data normalisation was performed using nSolver software followed by application of Bonferroni test for multiple comparisons using Graphpad Prism software to determine significantly differentially expressed genes. The 11 most significantly differentially expressed genes (*P*\<0.05) are shown.](bjc201581f1){#fig1}

![**The correlation between *STAT1* and *CXCL10* expression.** Pearson\'s correlation analysis (using Graphpad Prism software) showing significant positive correlation between *STAT1* and *CXCL10* expression within the resistant (**A**) and sensitive (**B**) groups with *r*^2^=0.81 (*P*\<0.001) and *r*^2^=0.77 (*P*\<0.0002), respectively.](bjc201581f2){#fig2}

![**Immunohistochemical analysis of STAT1 in HGSC.** (**A**) The STAT1 antibody (Abcam no. ab2415, polyclonal rabbit anti-human STAT1) optimisation by IHC was performed in (a) normal adjacent to prostate tumour tissue (showing negative staining), (b) HGS ovarian tissue (showing negative staining) and (c) HGS ovarian tissue (showing positive staining). (**B**) Independent validation of STAT1 expression was performed on an HGSC tissue microarray. Representative IHC images of overall STAT1 expression in HGSC. (a) Tissue punch scored as 0 negative/absent, (b) tissue punch scored as 1 with weak expression, (c) tissue punch scored as 2 for moderate expression and (d) tissue punch scored as 3 for strong expression.](bjc201581f3){#fig3}

![**Kaplan--Meier survival analysis according to STAT1 expression by immunohistochemistry.** Survival data were derived from an independent validation cohort of 183 HGSC patients with follow-up information. Kaplan--Meier estimates showing significant (*P*=0.02) association between increased overall STAT1 expression and longer progression-free survival.](bjc201581f4){#fig4}

![**Kaplan--Meier survival analysis based on STAT1 expression and correlation with FIGO stage and overall survival.** (**A**) Survival analysis based on comparison of FIGO stage I (*n*=11) and II (*n*=24), illustrating significant (*P*=0.03) correlation between levels of STAT1 expression and disease stage in all patients of FIGO stage I and II. *N*=number of patients. (**B**) Survival analysis showing association of STAT1 with overall survival showing a trend, approaching significance (*P*=0.08) towards shorter survival and decreased STAT1 expression. *N*= number of patients.](bjc201581f5){#fig5}

###### Clinicopathological details of high-grade serous ovarian cancer patients in validation cohort

                                                                 **Low STAT1,** ***n*** **(%)**   **High STAT1,** ***n*** **(%)**   **Overall,** ***n*** **(%)**
  ------------------------------------------------------------- -------------------------------- --------------------------------- ------------------------------
  **Age**                                                                                                                          
  *N*                                                                          88                               95                              183
  Mean                                                                         60                               62                               61
  Median                                                                       60                               63                               62
  s.d.                                                                        11.0                              9.6                             10.4
  Min                                                                          34                               38                               34
  Max                                                                          82                               81                               82
  **FIGO**                                                                                                                         
  I/II                                                                     12 (13.6%)                       21 (22.1%)                        33 (18%)
  III/IV                                                                   76 (86.4%)                       74 (77.9%)                       150 (82%)
  **Residual disease**                                                                                                             
  Unknown                                                                   15 (17%)                         9 (9.5%)                        24 (13.1%)
  ≤1 cm                                                                     37 (42%)                        47 (49.5%)                       83 (45.4%)
  \>1 cm                                                                   36 (40.9%)                       39 (41.1%)                       76 (41.5%)
  **Treatment**                                                                                                                    
  Platinum/taxane                                                          70 (79.5%)                       85 (89.5%)                      155 (84.5%)
  Platinum/taxane+additional agent[a](#t1-fn3){ref-type="fn"}               4 (4.5%)                         7 (7.4%)                         11 (6%)
  Platinum                                                                  2 (2.3%)                          1 (1%)                          3 (1.6%)
  Taxane                                                                    1 (1.1%)                          1 (1%)                          2 (1.1%)
  Cisplatin/topotecan                                                       5 (5.7%)                          1 (1%)                          6 (3.3%)
  Cyclophosphamide/carboplatin                                              6 (6.8%)                             0                            6 (3.3%)

Abbreviations: FIGO=International Federation of Gynaecology and Obstetrics; STAT1=signal transducer and activator of transcription 1.

Clinicopathological details of the high-grade serous ovarian cancer (HGSC) cohort of 183 patients used for independent validation of STAT1 expression by immunohistochemistry.

Additional agent: placebo or ganitumab (AMG479) or nintedanib (BIBF1120) or bevacizumab.
